Apellis Pharmaceuticals I...

AI Score

XX

Unlock

18.16
0.00 (0.00%)
At close: Apr 17, 2025, 3:59 PM
18.55
2.12%
After-hours: Apr 17, 2025, 04:32 PM EDT
0.00%
Bid 17.93
Market Cap 2.28B
Revenue (ttm) 781.37M
Net Income (ttm) -197.88M
EPS (ttm) -1.6
PE Ratio (ttm) -11.35
Forward PE 106.85
Analyst Buy
Ask 18.8
Volume 1,275,613
Avg. Volume (20D) 1,949,767
Open 18.39
Previous Close 18.16
Day's Range 18.06 - 18.51
52-Week Range 17.48 - 50.98
Beta 0.84

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 9, 2017
Employees 705
Stock Exchange NASDAQ
Ticker Symbol APLS
Full Company Profile

Analyst Forecast

According to 18 analyst ratings, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 120.20% from the latest price.

Stock Forecasts

Next Earnings Release

Apellis Pharmaceuticals Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+3.7%
Apellis Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
3 months ago
+4.19%
Apellis Pharmaceuticals shares are trading higher after the company reported preliminary full-year 2024 U.S. net product revenues of $709 million.